{"id":50582,"date":"2022-11-07T23:02:19","date_gmt":"2022-11-07T22:02:19","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/arcturus-therapeutics-to-present-at-the-following-investor-conferences-in-november\/"},"modified":"2022-11-07T23:02:19","modified_gmt":"2022-11-07T22:02:19","slug":"arcturus-therapeutics-to-present-at-the-following-investor-conferences-in-november","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/arcturus-therapeutics-to-present-at-the-following-investor-conferences-in-november\/","title":{"rendered":"Arcturus Therapeutics to Present at the Following Investor Conferences in November"},"content":{"rendered":"<div>\n<p>SAN DIEGO&#8211;(BUSINESS WIRE)&#8211;Arcturus Therapeutics Holdings Inc. (the \u201cCompany,\u201d \u201cArcturus,\u201d Nasdaq: ARCT), a global, late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that the Company will present at the following investor conferences.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20221107006097\/en\/837248\/5\/arcturus-logo-blueback.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20221107006097\/en\/837248\/21\/arcturus-logo-blueback.jpg\"><\/a><\/p>\n<p>\n<b>Guggenheim 4<sup>th<\/sup> Annual Immunology and Neurology Day (Fireside Chat)<\/b>\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nTuesday, November 15, 2022 (2:45 p.m. ET)\n<\/li>\n<\/ul>\n<p>\n<b>34<sup>th<\/sup> Annual Piper Sandler Healthcare Conference<\/b> <b>(Presentation)<\/b>\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nTuesday, November 29, 2022 (11:30 a.m. ET)\n<\/li>\n<\/ul>\n<p>\nIf available, links can be found under the Investor Relations\/Events section of the Arcturus\u2019 <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fir.arcturusrx.com%2Finvestor-calendar&amp;esheet=52963268&amp;newsitemid=20221107006097&amp;lan=en-US&amp;anchor=website&amp;index=1&amp;md5=efc94aabe12db3407bb5b423efd3ba12\" rel=\"nofollow noopener\" shape=\"rect\">website<\/a>.\n<\/p>\n<p>\n<b>About Arcturus Therapeutics<\/b>\n<\/p>\n<p>\nFounded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a global, late-stage clinical mRNA medicines and vaccines company with enabling technologies: (i) LUNAR\u00ae lipid-mediated delivery, (ii) STARR\u2122 mRNA Technology (samRNA) and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus\u2019 diverse pipeline of RNA therapeutic and vaccine candidates includes mRNA vaccine programs for SARS-CoV-2 (COVID-19) and Influenza, and other programs to potentially treat ornithine transcarbamylase (OTC) deficiency, and cystic fibrosis, along with partnered programs including glycogen storage disease type III, and hepatitis B virus. Arcturus\u2019 versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, self-amplifying RNA, antisense RNA, circular RNA, DNA, and gene editing therapeutics. Arcturus\u2019 technologies are covered by its extensive patent portfolio (patents and patent applications issued in the U.S., Europe, Japan, China and other countries). For more information, visit <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.ArcturusRx.com&amp;esheet=52963268&amp;newsitemid=20221107006097&amp;lan=en-US&amp;anchor=www.ArcturusRx.com&amp;index=2&amp;md5=3b2cb79e0e23270877d2ae3ee2cc93d5\" rel=\"nofollow noopener\" shape=\"rect\">www.ArcturusRx.com<\/a>. In addition, please connect with us on <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FArcturusRx&amp;esheet=52963268&amp;newsitemid=20221107006097&amp;lan=en-US&amp;anchor=Twitter&amp;index=3&amp;md5=fbf89eba69f14caa00ddbf12e847ea46\" rel=\"nofollow noopener\" shape=\"rect\">Twitter<\/a> and <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Farcturus-therapeutics&amp;esheet=52963268&amp;newsitemid=20221107006097&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=4&amp;md5=f0dc6ed51c98ef0726b8cd6940991755\" rel=\"nofollow noopener\" shape=\"rect\">LinkedIn<\/a>.\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\n<b>IR and Media Contacts<\/b><br \/>Arcturus Therapeutics<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#x61;&#x69;&#x6c;&#x74;&#x6f;&#x3a;&#x49;&#x52;&#x40;&#x61;&#114;&#99;&#116;&#117;&#114;&#117;&#115;rx&#46;com\" rel=\"nofollow noopener\" shape=\"rect\">&#x49;&#x52;&#x40;&#x61;&#x72;&#x63;&#x74;&#117;&#114;&#117;&#115;&#114;x&#46;co&#x6d;<\/a>\n<\/p>\n<p>\nKendall Investor Relations<br \/>\n<br \/>Carlo Tanzi, Ph.D.<br \/>\n<br \/>(617) 914-0008<br \/>\n<br \/><a target=\"_blank\" href=\"m&#97;&#105;&#x6c;&#x74;&#x6f;:c&#116;&#97;&#x6e;&#x7a;&#x69;&#64;&#107;&#101;&#110;&#x64;&#x61;&#x6c;l&#105;&#114;&#x2e;&#x63;&#x6f;m\" rel=\"nofollow noopener\" shape=\"rect\">ctanzi&#64;kendallir&#46;com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>SAN DIEGO&#8211;(BUSINESS WIRE)&#8211;Arcturus Therapeutics Holdings Inc. (the \u201cCompany,\u201d \u201cArcturus,\u201d Nasdaq: ARCT), a global, late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that the Company will present at the following investor conferences. Guggenheim 4th Annual Immunology and Neurology Day &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/arcturus-therapeutics-to-present-at-the-following-investor-conferences-in-november\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-50582","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Arcturus Therapeutics to Present at the Following Investor Conferences in November - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/arcturus-therapeutics-to-present-at-the-following-investor-conferences-in-november\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Arcturus Therapeutics to Present at the Following Investor Conferences in November - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"SAN DIEGO&#8211;(BUSINESS WIRE)&#8211;Arcturus Therapeutics Holdings Inc. (the \u201cCompany,\u201d \u201cArcturus,\u201d Nasdaq: ARCT), a global, late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that the Company will present at the following investor conferences. Guggenheim 4th Annual Immunology and Neurology Day ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/arcturus-therapeutics-to-present-at-the-following-investor-conferences-in-november\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-11-07T22:02:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221107006097\/en\/837248\/21\/arcturus-logo-blueback.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/arcturus-therapeutics-to-present-at-the-following-investor-conferences-in-november\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/arcturus-therapeutics-to-present-at-the-following-investor-conferences-in-november\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Arcturus Therapeutics to Present at the Following Investor Conferences in November\",\"datePublished\":\"2022-11-07T22:02:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/arcturus-therapeutics-to-present-at-the-following-investor-conferences-in-november\\\/\"},\"wordCount\":292,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/arcturus-therapeutics-to-present-at-the-following-investor-conferences-in-november\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221107006097\\\/en\\\/837248\\\/21\\\/arcturus-logo-blueback.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/arcturus-therapeutics-to-present-at-the-following-investor-conferences-in-november\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/arcturus-therapeutics-to-present-at-the-following-investor-conferences-in-november\\\/\",\"name\":\"Arcturus Therapeutics to Present at the Following Investor Conferences in November - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/arcturus-therapeutics-to-present-at-the-following-investor-conferences-in-november\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/arcturus-therapeutics-to-present-at-the-following-investor-conferences-in-november\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221107006097\\\/en\\\/837248\\\/21\\\/arcturus-logo-blueback.jpg\",\"datePublished\":\"2022-11-07T22:02:19+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/arcturus-therapeutics-to-present-at-the-following-investor-conferences-in-november\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/arcturus-therapeutics-to-present-at-the-following-investor-conferences-in-november\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/arcturus-therapeutics-to-present-at-the-following-investor-conferences-in-november\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221107006097\\\/en\\\/837248\\\/21\\\/arcturus-logo-blueback.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221107006097\\\/en\\\/837248\\\/21\\\/arcturus-logo-blueback.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/arcturus-therapeutics-to-present-at-the-following-investor-conferences-in-november\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Arcturus Therapeutics to Present at the Following Investor Conferences in November\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Arcturus Therapeutics to Present at the Following Investor Conferences in November - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/arcturus-therapeutics-to-present-at-the-following-investor-conferences-in-november\/","og_locale":"en_US","og_type":"article","og_title":"Arcturus Therapeutics to Present at the Following Investor Conferences in November - Pharma Trend","og_description":"SAN DIEGO&#8211;(BUSINESS WIRE)&#8211;Arcturus Therapeutics Holdings Inc. (the \u201cCompany,\u201d \u201cArcturus,\u201d Nasdaq: ARCT), a global, late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that the Company will present at the following investor conferences. Guggenheim 4th Annual Immunology and Neurology Day ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/arcturus-therapeutics-to-present-at-the-following-investor-conferences-in-november\/","og_site_name":"Pharma Trend","article_published_time":"2022-11-07T22:02:19+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221107006097\/en\/837248\/21\/arcturus-logo-blueback.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/arcturus-therapeutics-to-present-at-the-following-investor-conferences-in-november\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/arcturus-therapeutics-to-present-at-the-following-investor-conferences-in-november\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Arcturus Therapeutics to Present at the Following Investor Conferences in November","datePublished":"2022-11-07T22:02:19+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/arcturus-therapeutics-to-present-at-the-following-investor-conferences-in-november\/"},"wordCount":292,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/arcturus-therapeutics-to-present-at-the-following-investor-conferences-in-november\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221107006097\/en\/837248\/21\/arcturus-logo-blueback.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/arcturus-therapeutics-to-present-at-the-following-investor-conferences-in-november\/","url":"https:\/\/pharma-trend.com\/en\/arcturus-therapeutics-to-present-at-the-following-investor-conferences-in-november\/","name":"Arcturus Therapeutics to Present at the Following Investor Conferences in November - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/arcturus-therapeutics-to-present-at-the-following-investor-conferences-in-november\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/arcturus-therapeutics-to-present-at-the-following-investor-conferences-in-november\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221107006097\/en\/837248\/21\/arcturus-logo-blueback.jpg","datePublished":"2022-11-07T22:02:19+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/arcturus-therapeutics-to-present-at-the-following-investor-conferences-in-november\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/arcturus-therapeutics-to-present-at-the-following-investor-conferences-in-november\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/arcturus-therapeutics-to-present-at-the-following-investor-conferences-in-november\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221107006097\/en\/837248\/21\/arcturus-logo-blueback.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221107006097\/en\/837248\/21\/arcturus-logo-blueback.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/arcturus-therapeutics-to-present-at-the-following-investor-conferences-in-november\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Arcturus Therapeutics to Present at the Following Investor Conferences in November"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/50582","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=50582"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/50582\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=50582"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=50582"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=50582"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}